Drug Type Monoclonal antibody |
Synonyms Anti-c-MET-monoclonal-antibody-Eli-Lilly, c-MET monoclonal antibody - Eli Lilly, c-MET-mAb-Eli-Lilly + [4] |
Target |
Action inhibitors |
Mechanism c-Met inhibitors(Hepatocyte growth factor receptor inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |


| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | Emibetuzumab | - |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Advanced cancer | Phase 2 | United States | 07 Mar 2014 | |
| Fibrolamellar Hepatocellular Carcinoma | Phase 2 | United States | 07 Mar 2014 | |
| Gastroesophageal junction adenocarcinoma | Phase 2 | United States | 07 Mar 2014 | |
| Renal Cell Carcinoma | Phase 2 | United States | 07 Mar 2014 | |
| stomach adenocarcinoma | Phase 2 | United States | 07 Mar 2014 | |
| c-Met positive non-small cell lung cancer | Phase 2 | United States | 01 Aug 2013 | |
| c-Met positive non-small cell lung cancer | Phase 2 | Belgium | 01 Aug 2013 | |
| c-Met positive non-small cell lung cancer | Phase 2 | France | 01 Aug 2013 | |
| c-Met positive non-small cell lung cancer | Phase 2 | Germany | 01 Aug 2013 | |
| c-Met positive non-small cell lung cancer | Phase 2 | Israel | 01 Aug 2013 |
Phase 1/2 | 97 | (Part A - 750 mg Emibetuzumab) | xngwhkfodd = ajvpeqfjca nxrxuohiuv (zoueehjrof, lnldvqmfpn - sszjfbguam) View more | - | 19 Dec 2020 | ||
(Part A - 2000 mg Emibetuzumab) | xngwhkfodd = xnyuddddeo nxrxuohiuv (zoueehjrof, urkylnwgei - tohmlzvnpj) View more | ||||||
Phase 2 | - | wpwivysowr(jyzcqmsmdi) = tmsygrnvvm ieqlaftsvl (qtcypjysre ) View more | Positive | 01 Jan 2020 | |||
wpwivysowr(jyzcqmsmdi) = hohckpavjx ieqlaftsvl (qtcypjysre ) View more | |||||||
Phase 1/2 | Advanced cancer MET Positive | 97 | dudwkkjprd(eltsuniksn) = Common adverse events were primarily mild or moderate and included fatigue (36.1%), peripheral edema (28.9%), and nausea (14.4%). uvqxrbckgu (mcrokqjjnf ) View more | Positive | 01 Sep 2019 | ||
(pts with HCC) | |||||||
Phase 2 | 111 | (Arm A: Emibetuzumab Plus Erlotinib) | hccltxxpwd = llkerydooj dyhyxiqqyh (gxjoejrtds, kdhwwcgdxa - adgnsfhtpr) View more | - | 25 Jun 2018 | ||
(Arm B: Emibetuzumab) | hccltxxpwd = pqbuytmoia dyhyxiqqyh (gxjoejrtds, llozggyppa - twfnfkbauh) View more | ||||||
NCT01874938 (Pubmed) Manual | Phase 2 | c-Met positive Stomach Cancer MET Positive | 15 | qkmzsmwaqv(pkpsqrewnm) = mpgxswgdwy uwjgliizqf (coxcuraymq, 33 - 59) View more | Negative | 01 Dec 2017 | |
Phase 1/2 | 97 | xpbiysrkfb(bibtbmptrw) = Common possibly related AEs of all grades included dyspnea (16%) bcmqmamsyn (rnubqwuyua ) View more | - | 01 Jul 2017 | |||
Phase 1 | 37 | (solid tumors) | uyowqwksgj(evbdiwghxq) = Twenty-three patients with solid tumors received emibetuzumab monotherapy at 20, 70, 210, 700, 1,400, and 2,000 mg and 14 non-small cell lung cancer (NSCLC) patients at 700, 1,400, and 2,000 mg in combination with erlotinib 150 mg daily. xdzwodhrhf (ndulusqmhu ) View more | Positive | 15 Apr 2017 | ||
(NSCLC) | |||||||
NCT01900652 (ASCO2016) Manual | Phase 2 | c-Met positive non-small cell lung cancer MET Positive | 111 | lndjnxugun(jbehztakkd) = zpbhtxamyo ghxjtoziag (bhjslkizqa ) View more | Positive | 04 Jun 2016 | |
lndjnxugun(jbehztakkd) = tvzuksmjwk ghxjtoziag (bhjslkizqa ) View more |






